SUPPLEMENTARY APPENDIX

Supplementary Design and Methods
Statistical analysis
Gene-expression data were preprocessed by GC-RMA.
1,2 The use of a modified version of the "documentation by value" (docval) 1,2 package allowed the assessment of gene expression as if a new patient's *cel-file had been part of the initial GC-RMA preprocessed gene-expression dataset. This enables calculation of gene expression-based proliferation indices (see below) or risk scores and usage of previously validated thresholds for a patient not part of the initial analysis-set. An R-script allowing this calculation can be found in Online Supplementary File S1. To assess the presence or absence of gene expression, the "Presence-Absence calls with Negative Probesets (PANP)" algorithm 3 was used. P values were adjusted for multiple testing controlling the false discovery rate, as defined by Benjamini and Hochberg, at a level of 5%. 4 For myeloma cells, the association of chromosomal aberrations and clinical parameters with gene expression was assessed using two-sample t-statistics. Differences in clinical parameters between defined groups were investigated using the exact Wilcoxon's rank-sum test. Correlations were assessed using Pearson's correlation coefficient, or Kendall's tau coefficient (for categorical variables), the relationship between categorical variables by Fisher's exact test. The presence of a translocation t(4;14) within the LR group was assessed using a call-based predictor. Table S6 ) were calculated as published. The HM1 cohort was used as a reference myeloma dataset for the initial calculation of the GPI (see also below).
Gene expression profiling-based classifications
The group attribution according to the molecular classification of myeloma was assessed on the same dataset and using the same method as within the original series.
7 It can also be found under the accession number Series GSE4581. TC-class assessment was performed as described by Bergsagel et al. 9 Probe-sets for Affymetrix HGU95A arrays were shifted to the corresponding probe-sets on U133 2.0 and MAS5 normalized data used. High-risk scores by Shaughnessy et al. (Shaughnessy-HR) 10 and Decaux et al. (Decaux-HR) 11 were calculated as described by the respective authors, i.e. using normalization protocols (MAS5 in the case of the Shaughnessy-HR score) and cut-offs. An optimal threshold for LDH was calculated by maximum log-rank statistics, (R, maxstat-package). An effect was considered as statistically significant if the P value of its corresponding statistical test was not higher than 0.05. All statistical computations were performed using R 12 version 2.8.1, and Bioconductor, 13 version 2.3.
Calculation of the gene expression-based proliferation index
The gene expression-based proliferation index was calculated as follows. In brief, genes were selected from those overexpressed in proliferating cells [malignant: human myeloma cell lines (HMCL), benign: polyclonal plasmablastic cells (PPC)] compared to in non-proliferating cells [normal bone marrow plasma cells (BMPC) and memory B cells (MBC)]. Here, four comparisons between the groups were made, (i) HMCL versus MBC, (ii) HMCL versus BMPC, (iii) PPC versus BMPC and (iv) PPC versus MBC by a one-sided t-test, with the alternative hypothesis that expression values of HMCL and PPC are greater than those for BMPC and MBC in each comparison. P values were permutation-adjusted regarding a family wise error rate with an α-level of 0.025. To adjust for comparing each group twice, the α-level was halved to 0.0125. Only genes statistically significant in each of the four comparisons were retained for the index. To select biologically relevant genes (in terms of proliferation) only genes with the gene-ontology term "cell proliferation" or "cell cycle" were retained. Thus, 50 genes (57 probe-sets) were included in the final index. For genes with more than one probe-set per gene, the probe-set with the highest variance within the HM1 cohort was selected. The index was calculated as follows. Given that proliferation-genes determined as stated above are over-expressed by definition, the individual gene expression based-proliferation index for each sample was calculated as the sum of expression values of each of the 50 genes in an individual sample. For genes not expressed as judged by PANP, the expression level of the respective gene was defined as 0.
Online Supplementary Figure  S1 . The plasma cell labeling index (ordinate, PCLI) for the gene expression-based proliferation index (GPI) divided into (A) two groups according to values below or above the median (P=0.003, n=66) and (B) three groups high/median/low (low versus medium P=0.01, low or medium versus high P=n.s. due to low number (n=4) of measurements in the GPI "high" group; n=66). 
